{"id":58459,"date":"2026-02-28T15:09:15","date_gmt":"2026-02-28T07:09:15","guid":{"rendered":"https:\/\/flcube.com\/?p=58459"},"modified":"2026-02-28T15:09:16","modified_gmt":"2026-02-28T07:09:16","slug":"olumiant-wins-chmp-positive-opinion-for-pediatric-alopecia-jak-inhibitor-nears-eu-approval-for-teens-with-severe-aa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58459","title":{"rendered":"Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA"},"content":{"rendered":"\n<p><strong>Eli Lilly (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE:\u202fLLY<\/a>)<\/strong> and <strong>Incyte (<a href=\"https:\/\/www.google.com\/finance\/quote\/INCY:NASDAQ\">NASDAQ:\u202fINCY<\/a>)<\/strong> announced that the <strong>European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP)<\/strong> issued a <strong>positive opinion<\/strong> for <strong>Olumiant (baricitinib)<\/strong> for the treatment of <strong>adolescents aged 12 to &lt;\u202f18 years<\/strong> with <strong>severe alopecia areata (AA)<\/strong>. The recommendation expands Olumiant&#8217;s AA franchise to <strong>pediatric patients<\/strong>, following <strong>prior adult approvals<\/strong> in 2022 that established baricitinib as the <strong>first JAK inhibitor<\/strong> approved for severe AA in the US and EU.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Eli Lilly (NYSE:\u202fLLY) + Incyte (NASDAQ:\u202fINCY)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Olumiant (baricitinib)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Once\u2011daily oral JAK inhibitor<\/td><\/tr><tr><td><strong>Discovery\/Origination<\/strong><\/td><td>Incyte; licensed to Lilly<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>EMA CHMP (positive opinion); EC (final decision pending)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Severe alopecia areata (AA)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adolescents aged <strong>12 to &lt;\u202f18 years<\/strong><\/td><\/tr><tr><td><strong>Prior AA Approvals<\/strong><\/td><td>Adults \u2013 US (2022), EU (2022), Japan<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-olumiant-global-approval-status\">Olumiant Global Approval Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Approval Status<\/th><th>Geography<\/th><\/tr><\/thead><tbody><tr><td><strong>Rheumatoid arthritis (moderate\u2011severe)<\/strong><\/td><td>Approved<\/td><td>US + 75+ countries<\/td><\/tr><tr><td><strong>Atopic dermatitis (moderate\u2011severe, systemic candidates)<\/strong><\/td><td>Approved<\/td><td>40+ countries (\u2265\u202f2 years old)<\/td><\/tr><tr><td><strong>Alopecia areata (severe)<\/strong> \u2013 Adults<\/td><td>Approved<\/td><td>US, Europe, Japan<\/td><\/tr><tr><td><strong>Alopecia areata (severe)<\/strong> \u2013 Adolescents<\/td><td>CHMP positive opinion<\/td><td>EU (pending EC decision)<\/td><\/tr><tr><td><strong>COVID\u201119 (hospitalized patients)<\/strong><\/td><td>Approved<\/td><td>Multiple countries<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pediatric AA Unmet Need:<\/strong> Severe alopecia areata affects <strong>adolescents disproportionately<\/strong>, with significant <strong>psychosocial impact<\/strong> (school absence, depression, social isolation); existing therapies (corticosteroids, immunosuppressants) have limited efficacy and safety concerns\u2014Olumiant offers <strong>targeted, oral alternative<\/strong>.<\/li>\n\n\n\n<li><strong>JAK Inhibitor Leadership:<\/strong> Baricitinib&#8217;s <strong>first\u2011to\u2011market position<\/strong> in AA (adult 2022, adolescent 2026) establishes <strong>class leadership<\/strong> vs. competitors (Pfizer&#8217;s ritlecitinib, Concert\/Galderma&#8217;s deuruxolitinib).<\/li>\n\n\n\n<li><strong>Label Expansion Momentum:<\/strong> The <strong>adolescent AA indication<\/strong> adds to Olumiant&#8217;s <strong>diverse immunology portfolio<\/strong> (RA, AD, AA), supporting <strong>franchise growth<\/strong> amid competitive pressure in rheumatology.<\/li>\n\n\n\n<li><strong>Oral Convenience:<\/strong> <strong>Once\u2011daily oral administration<\/strong> vs. injectable biologics improves <strong>adolescent adherence<\/strong> and <strong>quality of life<\/strong>, critical for chronic disease management in young patients.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Alopecia Areata Prevalence<\/strong><\/td><td>~\u202f2% lifetime risk; severe form affects ~\u202f20% of patients; adolescent onset common<\/td><\/tr><tr><td><strong>AA Market Size<\/strong><\/td><td>~\u202f$1\u202fbillion addressable globally; growing recognition of disease burden and treatment demand<\/td><\/tr><tr><td><strong>JAK Inhibitor Competition<\/strong><\/td><td>Ritlecitinib (Pfizer) approved 2023; deuruxolitinib (Concert\/Galderma) Phase III; baricitinib maintains first\u2011mover and oral advantage<\/td><\/tr><tr><td><strong>Pediatric Dermatology<\/strong><\/td><td>Limited approved systemic therapies; Olumiant adolescent approval addresses significant unmet need<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding EC final approval, commercial launch timelines, and pediatric market uptake. Actual results may differ due to risks including reimbursement negotiations, competitive JAK inhibitor launches, and long\u2011term safety monitoring in adolescent populations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly (NYSE:\u202fLLY) and Incyte (NASDAQ:\u202fINCY) announced that the European Medicines Agency&#8217;s (EMA) Committee for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58460,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,199,999,998,911,15],"class_list":["post-58459","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-eli-lilly","tag-incyte-pharmaceuticals","tag-nasdaq-incy","tag-nyse-lly","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly (NYSE:\u202fLLY) and Incyte (NASDAQ:\u202fINCY) announced that the European Medicines Agency&#039;s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Olumiant (baricitinib) for the treatment of adolescents aged 12 to &lt;\u202f18 years with severe alopecia areata (AA). The recommendation expands Olumiant&#039;s AA franchise to pediatric patients, following prior adult approvals in 2022 that established baricitinib as the first JAK inhibitor approved for severe AA in the US and EU.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58459\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly (NYSE:\u202fLLY) and Incyte (NASDAQ:\u202fINCY) announced that the European Medicines Agency&#039;s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Olumiant (baricitinib) for the treatment of adolescents aged 12 to &lt;\u202f18 years with severe alopecia areata (AA). The recommendation expands Olumiant&#039;s AA franchise to pediatric patients, following prior adult approvals in 2022 that established baricitinib as the first JAK inhibitor approved for severe AA in the US and EU.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58459\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-28T07:09:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-28T07:09:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2804.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58459#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58459\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA\",\"datePublished\":\"2026-02-28T07:09:15+00:00\",\"dateModified\":\"2026-02-28T07:09:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58459\"},\"wordCount\":421,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58459#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2804.webp\",\"keywords\":[\"Auto-immune\",\"Eli Lilly\",\"Incyte Pharmaceuticals\",\"NASDAQ: INCY\",\"NYSE: LLY\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58459#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58459\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58459\",\"name\":\"Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58459#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58459#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2804.webp\",\"datePublished\":\"2026-02-28T07:09:15+00:00\",\"dateModified\":\"2026-02-28T07:09:16+00:00\",\"description\":\"Eli Lilly (NYSE:\u202fLLY) and Incyte (NASDAQ:\u202fINCY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Olumiant (baricitinib) for the treatment of adolescents aged 12 to &lt;\u202f18 years with severe alopecia areata (AA). The recommendation expands Olumiant&#039;s AA franchise to pediatric patients, following prior adult approvals in 2022 that established baricitinib as the first JAK inhibitor approved for severe AA in the US and EU.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58459#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58459\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58459#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2804.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2804.webp\",\"width\":1080,\"height\":608,\"caption\":\"Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58459#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly (NYSE:\u202fLLY) and Incyte (NASDAQ:\u202fINCY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Olumiant (baricitinib) for the treatment of adolescents aged 12 to &lt;\u202f18 years with severe alopecia areata (AA). The recommendation expands Olumiant&#039;s AA franchise to pediatric patients, following prior adult approvals in 2022 that established baricitinib as the first JAK inhibitor approved for severe AA in the US and EU.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58459","og_locale":"en_US","og_type":"article","og_title":"Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA","og_description":"Eli Lilly (NYSE:\u202fLLY) and Incyte (NASDAQ:\u202fINCY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Olumiant (baricitinib) for the treatment of adolescents aged 12 to &lt;\u202f18 years with severe alopecia areata (AA). The recommendation expands Olumiant&#039;s AA franchise to pediatric patients, following prior adult approvals in 2022 that established baricitinib as the first JAK inhibitor approved for severe AA in the US and EU.","og_url":"https:\/\/flcube.com\/?p=58459","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-28T07:09:15+00:00","article_modified_time":"2026-02-28T07:09:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2804.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58459#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58459"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA","datePublished":"2026-02-28T07:09:15+00:00","dateModified":"2026-02-28T07:09:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58459"},"wordCount":421,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58459#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2804.webp","keywords":["Auto-immune","Eli Lilly","Incyte Pharmaceuticals","NASDAQ: INCY","NYSE: LLY","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58459#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58459","url":"https:\/\/flcube.com\/?p=58459","name":"Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58459#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58459#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2804.webp","datePublished":"2026-02-28T07:09:15+00:00","dateModified":"2026-02-28T07:09:16+00:00","description":"Eli Lilly (NYSE:\u202fLLY) and Incyte (NASDAQ:\u202fINCY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Olumiant (baricitinib) for the treatment of adolescents aged 12 to &lt;\u202f18 years with severe alopecia areata (AA). The recommendation expands Olumiant&#039;s AA franchise to pediatric patients, following prior adult approvals in 2022 that established baricitinib as the first JAK inhibitor approved for severe AA in the US and EU.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58459#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58459"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58459#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2804.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2804.webp","width":1080,"height":608,"caption":"Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58459#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia \u2013 JAK Inhibitor Nears EU Approval for Teens with Severe AA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2804.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58459"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58459\/revisions"}],"predecessor-version":[{"id":58461,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58459\/revisions\/58461"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58460"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}